Previous 10 | Next 10 |
Drug developer Theravance Biopharma (NASDAQ: TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ: INVA) . Shareholders in Innoviva received a dividend of Theravance Biopharma stock. The R&am...
DUBLIN , Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38 th Annual J.P. Morgan Healt...
Theravance Biopharma (NASDAQ: TBPH ) enters a global license pact with Pfizer (NYSE: PFE ) for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. More news on: Theravance Biopharma, Inc., Pfizer Inc., H...
DUBLIN and NEW YORK , Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license ...
DUBLIN , Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) in...
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Seth Klarman’s Baupost Group Holdings...
Theravance Biopharma, Inc. (TBPH) Q3 2019 Earnings Conference Call November 5, 2019 17:00 ET Corporate Participants Jessica Stitt - Vice President, Finance and Investor Relations Rick Winningham - Chief Executive Officer Brett Haumann - Chief Medical Officer Frank Pasqualone - ...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q3 earnings Read more ...
DUBLIN , Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a corporate presentation at the 28th Annual Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 , at 3:00 p.m....
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q3 2019 Earnings Call Nov 5, 2019 , 5:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...